+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America IVF (in-vitro fertilization) Market Outlook, 2029

  • PDF Icon

    Report

  • 76 Pages
  • May 2024
  • Region: North America
  • Bonafide Research
  • ID: 5978339
10% Free customization
1h Free Analyst Time
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

One of the biggest and most active markets for in vitro fertilisation (IVF) worldwide is the North American market. North America is a key centre for IVF treatments and related services due to a mix of highly developed healthcare infrastructure, high spending incomes, and generally positive views towards reproductive technologies. Numerous significant trends influencing the IVF market in North America are shown by market analysis. First, as more couples become aware of their possibilities for conception and as infertility rates rise, there has been a consistent rise in the demand for IVF treatments. Due to the increased demand, there are now many assisted reproductive technology (ART) centres and specialty fertility clinics in the area.

These facilities provide a variety of treatments, from sophisticated IVF operations to simple fertility assessments. Furthermore, improvements in patient outcomes and success rates have been facilitated by technology breakthroughs and innovations in IVF techniques. In terms of reproductive medicine, North America is leading the way in research and development. Continuous efforts are being made to improve laboratory methods, streamline procedures, and create novel treatment choices for a range of infertility-related issues. In addition, the IVF industry in North America is competitive, with both well-established firms and up-and-coming startups fighting for market dominance.

In order to stand out from the competitors and draw in customers, more money is being spent on patient outreach, marketing, and customer service programmes. Additionally, businesses frequently use strategic alliances, mergers, and acquisitions as a means of growing their market share and fortifying their market positions. The IVF market in North America is significantly shaped by regulations as well. Although state and provincial laws regulating IVF procedures differ, a general framework is in place to guarantee the security, effectiveness, and moral conduct of reproductive treatments. In order to keep their accreditation and licence, clinics and ART centres must adhere to strict regulations.

This helps stakeholders and patients have faith in the high calibre of treatment that is being offered. The environment of the IVF market in North America is dynamic and ever-changing, driven by factors such as growing demand, technical advancements, competitive dynamics, and regulatory supervision. Stakeholders in the industry as a whole are well-positioned to benefit from development, innovation, and the continued leadership in reproductive medicine in the region, which will continue to enhance fertility treatment in North America and abroad.

According to the research report, the North America IVF market was valued at more than USD 7 Billion by 2024-29. A number of important reasons have contributed to the IVF market's consistent rise in North America in recent years. The rising rate of infertility among couples in the area is one important factor driving this growth. An increasing number of people and couples are turning to IVF therapy as a result of causes like delayed childbirth, lifestyle modifications, environmental variables, and the rising prevalence of diseases like polycystic ovarian syndrome (PCOS). Furthermore, the number of individuals who can benefit from treatment has increased and success rates for IVF and assisted reproductive technologies (ART) have risen.

Preimplantation genetic testing (PGT), time-lapse embryo imaging, and customized treatment plans are examples of innovations that have improved the effectiveness and efficiency of in vitro fertilisation (IVF) operations, increasing their accessibility and attractiveness to a wider range of patients. The growing public acceptability and understanding of fertility treatments is another factor propelling the growth of the IVF market in North America. As reproductive health becomes less of a taboo topic and more openly discussed, more people and couples are exploring options like in vitro fertilisation (IVF) to achieve parenthood.

Further driving market expansion has been the increased insurance coverage and availability of financial aid programmes for fertility treatments, which have reduced the cost of IVF and increased its accessibility for a larger number of patients. A strong ecosystem of fertility clinics, ART facilities, research institutes, and healthcare professionals that work together to further the field of reproductive medicine has also helped the North American IVF business. This cooperative setting encourages creativity, information exchange, and the sharing of best practices, which promotes ongoing advancements in IVF methods and patient care.

Major Drivers:

  • Increasing Prevalence of Infertility: A significant driver is the rising incidence of infertility among couples in North America. Factors such as delayed childbearing, lifestyle changes, environmental factors, and medical conditions contribute to higher rates of infertility, necessitating the need for fertility treatments like IVF.
  • Improving Accessibility and Affordability: Greater insurance coverage and financial assistance programs for fertility treatments have made IVF more accessible and affordable to a wider range of patients. This has reduced financial barriers and increased the number of individuals who can pursue IVF treatment.

Major Challenges:

  • Cost and Affordability: IVF treatment can be prohibitively expensive for many patients. The high costs associated with procedures, medications, and additional services pose a significant barrier to access. Insurance coverage for IVF varies widely, and even when available, it often comes with limitations or out-of-pocket expenses. As a result, affordability remains a significant challenge, preventing some individuals and couples from pursuing IVF treatment despite its potential benefits.
  • Health Disparities and Access to Care: Disparities in access to IVF treatment exist along lines of race, ethnicity, socioeconomic status, and geographic location. Certain populations face greater barriers to care due to factors such as lack of insurance coverage, limited access to fertility clinics, cultural stigmas, or language barriers. Addressing these disparities requires targeted efforts to improve access, increase awareness, and reduce barriers to care for underserved communities.

Major Trends:

  • Rise of Elective Egg Freezing: Elective egg freezing, also known as oocyte cryopreservation, is emerging as a significant trend in the IVF market, particularly among women who wish to preserve their fertility for future family planning. Increasing societal acceptance, advancements in freezing techniques and greater awareness of fertility preservation options are driving the demand for elective egg freezing services.
  • Personalized Medicine and Treatment Protocols: there is a growing emphasis on personalized medicine and tailored treatment protocols in the IVF market. Providers are increasingly utilizing patient-specific factors such as age, ovarian reserve, genetic profile, and previous treatment history to customize IVF protocols and optimize outcomes. Personalized approaches aim to improve success rates while minimizing risks and side effects for individual patients.
frozen donor cycles allow for the selection of high-quality embryos from a diverse pool of donors, enhancing the likelihood of successful implantation and pregnancy.

An examination of the IVF market's segmentation by cycle type, with a particular emphasis on frozen donor and fresh donor cycles, offers important insights into the workings and patterns of the assisted reproductive technology (ART) sector. In frozen donor IVF cycles, the recipient's uterus receives thawed frozen eggs or embryos from donors, which are then used in the IVF process. Increased scheduling flexibility, a lower chance of ovarian hyper stimulation syndrome (OHSS), and possibly lower costs in comparison to fresh donor cycles are just a few benefits of this cycle type.

In contrast, fresh donor IVF cycles involve the retrieval of eggs from a donor, fertilization with sperm in a laboratory setting, and the transfer of resulting embryos to the recipient's uterus within the same menstrual cycle. Fresh donor cycles provide the advantage of using freshly harvested eggs, which may lead to higher success rates due to their optimal quality and viability. However, they also entail coordination between the donors and recipients menstrual cycles, as well as the potential for ovarian hyper stimulation and associated complications.

Segmentation analysis by cycle type allows researchers and practitioners to evaluate the utilization patterns, success rates, and patient preferences associated with frozen donor IVF cycles versus fresh donor IVF cycles. It enables the identification of trends such as shifts in clinical practice, advancements in cryopreservation techniques, and changes in patient demographics driving the demand for specific cycle types. Healthcare professionals, legislators, and industry stakeholders must comprehend the subtle differences between frozen donor IVF cycles and fresh donor IVF cycles through segmentation analysis. It facilitates well-informed choices on treatment plans, resource distribution, and the creation of tactics to maximize patient.

This technique has been a cornerstone of fertility treatment for decades, offering a widely accessible and effective option for couples facing infertility


An examination of the IVF market segmentation by technique, with a particular emphasis on conventional IVF and IVF with Intracytoplasmic Sperm Injection (ICSI), provides important information about the usage trends, success rates, and clinical results linked to each technique in the context of assisted reproductive technology (ART). In conventional IVF, sperm and eggs are fertilized in a lab dish, allowing natural selection to choose which sperm fertilizes the egg. Conventional IVF is appropriate for a number of infertility problems and is frequently the first course of treatment before more sophisticated methods are taken into account.

On the other hand, IVF with ICSI eliminates the requirement for sperm to pass through the egg's outer layer by injecting a single sperm directly into the egg. This method is very helpful when there may be a compromise in the quality or quantity of sperm, as in male factor infertility instances. In cases where traditional IVF has failed or when there are questions regarding the quality of the sperm, ICSI may be advised in order to increase fertilisation rates. Technique-specific segmentation analysis enables the evaluation of trends like the preference for ICSI over traditional IVF, differences in the success rates of the two procedures, and shifts in healthcare professionals' clinical practice preferences.

Stakeholders can use it to determine what influences the choice of treatment, such as physician experience, patient demographics, and infertility diagnoses. To maximize treatment results, resource allocation, and patient satisfaction in the ART market, segmentation analysis is necessary to comprehend the subtle differences between conventional IVF and IVF with ICSI. In the ever-changing field of reproductive care, it encourages the use of evidence to guide decisions on treatment plans, infrastructure and technology purchases, and the creation of plans tailored to the requirements and preferences of individual patients.

These facilities cater to a diverse patient population, ranging from individuals undergoing basic fertility assessments to those requiring advanced reproductive interventions such as IVF


The distribution, utilisation, and trends within the assisted reproductive technology (ART) business may be gained by doing a segmentation analysis of the IVF market by end-user, with a particular focus on hospitals and surgical centres. Offering specialised equipment, knowledgeable staff, and all-encompassing care to patients pursuing reproductive treatments, hospitals and surgical centres play a crucial role in the provision of IVF services. End-user segmentation facilitates the evaluation of utilisation patterns and preferences related to IVF services offered in hospital and surgical centre settings by academics and practitioners.

Trends such as the geographic distribution of IVF centres, variations in treatment protocols, and variances in patient demographics served by various facility types can all be identified using it. Healthcare professionals, legislators, and industry stakeholders must comprehend the subtleties of IVF treatments provided in hospitals and surgery centres through segmentation analysis. It facilitates well-informed choices about service planning, infrastructure development, and resource allocation to satisfy the changing requirements of patients pursuing reproductive care.

Additionally, collaboration and partnership opportunities between surgical centres, hospitals, and other stakeholders involved in the provision of IVF services are facilitated by segmentation analysis by end-user. Stakeholders can progress the delivery of fertility services in the ART market, improve patient outcomes, and increase access to high-quality IVF care by utilizing the assets and capabilities of various facility types.

In Mexico, an emerging market, rapid industrialization and urbanization fuel demand for IVF, especially in the beverage sector


A detailed geographical analysis of the IVF industry in North America is conducted, taking into account the various economic environments, consumer trends, and legal frameworks that exist in the US, Canada, and Mexico. Sustainability becomes a major factor in the United States, a developed market with strong manufacturing capabilities, as a result of strict laws and consumer demand for environmentally friendly products. Trends towards premiumization are thriving, especially in specialised foods and craft beverages, which increase the importance of IVF, which is renowned for its high calibre and status.

While sustainability and premiumization tendencies are comparable in Canada, the country's growth is driven by a growing middle class and developing sectors like natural health goods. Despite variations, sustainability remains a common theme, with all regions prioritizing environmental concerns and embracing glass as a sustainable packaging option. Moreover, innovation and customization flourish across regions, with manufacturers continuously adapting to meet evolving consumer preferences and industry standards. This regional analysis underscores the multifaceted nature of the North America IVF market, where regional nuances intersect with overarching trends to drive growth and innovation in the industry.

Industry development and market expansion are propelled by broad trends like premiumization, sustainability, and innovation in all three areas. Sustainability is still a major concern, with demand for IVF rising as a result of regulations, brands, and consumers giving eco-friendly packaging options top priority. IVF's significance is being further elevated by premiumization trends, especially in the premium food and beverage industries where consumers place a high value on quality, authenticity, and aesthetics. Variations in consumer tastes, industry standards, and legal needs are met by manufacturers who consistently innovate and customise their products to prosper in all countries.

Years considered in this report:

  • Historic year: 2018
  • Base year: 2023
  • Estimated year: 2024
  • Forecast year: 2029

Aspects covered in the report:

  • IVF market Outlook with its value and forecast along with its segments
  • Various drivers and challenges
  • On-going trends and developments
  • Top profiled companies
  • Strategic recommendations

By cycle:

  • Fresh Non-donor IVF Cycle
  • Frozen Non-donor IVF Cycle
  • Frozen donor IVF Cycle
  • Fresh donor IVF Cycle

By Conventional IVF:

  • Conventional IVF
  • IVF with ICSI (Instracytoplasmic Sperm Injection)
  • IVF With Donor Eggs
  • other

By End user:

  • Fertility Clinics
  • Hospital & Surgical Centers
  • Cryobanks
  • Research institute

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases.

After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. After this, the analysts made primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once they acquired the primary data, they started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.

Table of Contents

1. Executive Summary
2. Research Methodology
2.1. Secondary Research
2.2. Primary Data Collection
2.3. Market Formation & Validation
2.4. Report Writing, Quality Check & Delivery
3. Market Structure
3.1. Market Considerate
3.2. Assumptions
3.3. Limitations
3.4. Abbreviations
3.5. Sources
3.6. Definitions
4. Economic/Demographic Snapshot
5. Global In Vitro Fertilization Market Outlook
5.1. Market Size by Value
5.2. Market Share by Region
5.3. Market Size and Forecast, by Cycle
5.4. Market Size and Forecast, by Conentional IVF
5.5. Market Size and Forecast, by End user
6. North America In Vitro Fertilization Market Outlook
6.1. Market Size by Value
6.2. Market Share by Country
6.3. Market Size and Forecast, by Cycle
6.4. Market Size and Forecast, by Conentional IVF
6.5. Market Size and Forecast, by End user
7. Market Dynamics
7.1. Market Drivers & Opportunities
7.2. Market Restraints & Challenges
7.3. Market Trends
7.4. COVID-19 Effect
7.5. Supply Chain Analysis
7.6. Policy & Regulatory Framework
7.7. Industry Experts Views
7.8. United States In Vitro Fertilization Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast by Cycle
7.8.3. Market Size and Forecast by Conentional IVF
7.8.4. Market Size and Forecast by End user
7.9. Canada In Vitro Fertilization Market Outlook
7.9.1. Market Size by Value
7.9.2. Market Size and Forecast by Cycle
7.9.3. Market Size and Forecast by Conentional IVF
7.9.4. Market Size and Forecast by End user
7.10. Mexico In Vitro Fertilization Market Outlook
7.10.1. Market Size by Value
7.10.2. Market Size and Forecast by Cycle
7.10.3. Market Size and Forecast by Conentional IVF
7.10.4. Market Size and Forecast by End user
8. Competitive Landscape
8.1. Competitive Dashboard
8.2. Business Strategies Adopted by Key Players
8.3. Key Players Market Positioning Matrix
8.4. Porter's Five Forces
8.5. Company Profiles
8.5.1. Thermo Fisher Scientific Inc.
8.5.1.1. Company Snapshot
8.5.1.2. Company Overview
8.5.1.3. Financial Highlights
8.5.1.4. Geographic Insights
8.5.1.5. Business Segment & Performance
8.5.1.6. Product Portfolio
8.5.1.7. Key Executives
8.5.1.8. Strategic Moves & Developments
8.5.2. Vitrolife AB
8.5.3. Fujifilm Holdings Corporation
8.5.4. Merck KGaA
8.5.5. The Cooper Companies, Inc.
8.5.6. Esco Micro Pte. Ltd.
8.5.7. Hamilton Thorne Inc.
8.5.8. Cook Group Incorporated
9. Strategic Recommendations
10. Annexure
10.1. FAQs
10.2. Notes
10.3. Related Reports
11. Disclaimer
List of Figures
Figure 1: Global In Vitro Fertilization Market Size (USD Billion) by Region, 2023 & 2029
Figure 2: Market attractiveness Index, by Region 2029
Figure 3: Market attractiveness Index, by Segment 2029
Figure 4: Global In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 5: Global In Vitro Fertilization Market Share by Region (2023)
Figure 6: North America In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 7: North America In Vitro Fertilization Market Share by Country (2023)
Figure 8: US In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 9: Canada In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 10: Mexico In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 11: Competitive Dashboard of top 5 players, 2023
Figure 12: Porter's Five Forces of Global In Vitro Fertilization Market
List of Tables
Table 1: Global In Vitro Fertilization Market Snapshot, by Segmentation (2023 & 2029) (in USD Billion)
Table 2: Top 10 Counties Economic Snapshot 2022
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Global In Vitro Fertilization Market Size and Forecast, by Cycle (2018 to 2029F) (In USD Billion)
Table 6: Global In Vitro Fertilization Market Size and Forecast, by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 7: Global In Vitro Fertilization Market Size and Forecast, by End user (2018 to 2029F) (In USD Billion)
Table 8: North America In Vitro Fertilization Market Size and Forecast, by Cycle (2018 to 2029F) (In USD Billion)
Table 9: North America In Vitro Fertilization Market Size and Forecast, by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 10: North America In Vitro Fertilization Market Size and Forecast, by End user (2018 to 2029F) (In USD Billion)
Table 11: Influencing Factors for In Vitro Fertilization Market, 2023
Table 12: United States In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 13: United States In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 14: United States In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)
Table 15: Canada In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 16: Canada In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 17: Canada In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)
Table 18: Mexico In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 19: Mexico In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 20: Mexico In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc.
  • Vitrolife AB
  • Fujifilm Holdings Corporation
  • Merck KGaA
  • The Cooper Companies, Inc.
  • Esco Micro Pte. Ltd.
  • Hamilton Thorne Inc.
  • Cook Group Incorporated